High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...

Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.

Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...

Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...